Search results
10 sty 2024 · A multidisciplinary, multinational panel reviewed existing ASCO guidelines and conducted modified ADAPTE and formal consensus processes. Results. Four published resource-agnostic guidelines were adapted for resource-constrained settings; informing two rounds of formal consensus; recommendations received ≥75% agreement. Recommendations.
- ASCO Clinical Practice Guidelines | Journal of Clinical Oncology
Using the best available evidence, ASCO expert panels...
- Management of Hereditary Breast Cancer: American Society of Clinical ...
The recommendations provided for locoregional management of...
- ASCO Clinical Practice Guidelines | Journal of Clinical Oncology
Using the best available evidence, ASCO expert panels identify and develop practice recommendations for specific areas of cancer care that would benefit from the availability of practice guidelines.
3 kwi 2020 · The recommendations provided for locoregional management of nonmetastatic hereditary breast cancer are based on Expert Panel consensus because data from RCTs are lacking; most of the available data are derived from observational studies.
You can also access ASCO guidelines with the tap of your finger via our app, pocket cards, and podcast: Download the free ASCO Guidelines App for iPhone/iPad or Android. Access ASCO Guideline Pocket Cards, members are eligible to receive free digital access.
The ASCO Clinical Practice Guidelines Committee guideline process includes: a systematic literature review by ASCO guidelines staff. an expert panel provides critical review and evidence interpretation to inform guideline recommendations. final guideline approval by ASCO CPGC.
20 wrz 2022 · Purpose: To update the ASCO Biomarkers to Guide Systemic Therapy for Metastatic Breast Cancer (MBC) guideline. Methods: An Expert Panel conducted a systematic review to identify randomized clinical trials and prospective-retrospective studies from January 2015 to January 2022.
12 gru 2022 · The American Society of Clinical Oncology recently published two updated guidelines on issues related to the diagnosis and treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
